ERBB2 and gastric cancer: In the context of first-line therapy for patients with HER2-negative, unresectable advanced or recurrent GC or GEJC, the ATTRACTION-4 study investigated the comparative efficacy between nivolumab plus chemotherapy and placebo plus chemotherapy.